About the Editor
Lisa E. Davis, PharmD, FCCP, BCPS, BCOP, is the editor in chief of Pharmacy Practice in Focus: Oncology. Davis holds positions as a clinical pharmacist in early-phase clinical trial and breast cancer programs at the University of Arizona Cancer Center in Tucson and as a clinical professor of pharmacy practice and science at the University of Arizona R. Ken Coit College of Pharmacy. Davis also sits on the Hematology/Oncology Pharmacy Association Board of Directors and is a member of the Cancer Prevention and Control Program and scientific review committee at the University of Arizona Cancer Center.
Strategies to advance sex and gender equality nationally and globally in oncology have been initiated in recent years, which has helped to highlight ongoing inequalities in oncology care for sexual and gender minority (SGM) populations. In the US, social determinants of health affect women and SGM populations disproportionately in all areas of health care, including oncology.
The Lancet Commission on women, power, and cancer identifies and releases key findings that can inform quality cancer care, awareness, and policies that not only impact patients but also their caregivers and the oncology workforce.1 As cancer health care professionals, we can incorporate some of the commission’s recommendations regarding gender competencies into curricula, research, and practice, particularly as they relate to the provision of care. Two examples identified by the commission are sex-specific toxicity and treatment response, and patient-reported outcomes monitoring of toxicity or psychosocial stresses of cancer treatment.1
Women with cancer experience disparities across the entire cancer spectrum, including incidence, diagnosis, treatment, and adverse effects. Female sex is an established risk factor for severe symptomatic, hematologic, and nonhematologic toxicities associated with immunotherapy and certain anticancer agents and classes of drugs. Broadly, women also experience higher rates of toxicity, as reported in clinical trials for esophageal, gastric, lung, and colorectal cancers, as well as sarcomas and lymphomas; however, exceptions can be seen in trials of EGFR inhibitors for lung cancer and rituximab (Rituxan; Genentech) for non-Hodgkin lymphoma. Despite higher rates of toxicity, women also often have better reported response rates or survival outcomes compared with men in many but not all oncology clinical trials. These inconsistencies highlight highlight opportunities to improve the quality of demographic sex/gender reporting and analysis in clinical research.